Galapagos NV and AbbVie have extended their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase II program in Crohn's disease, and upon successful completion, AbbVie will pay Galapagos $50 million. AbbVie will be responsible for funding and performing clinical development beyond Phase II, as well as regulatory and commercialization activities.
"AbbVie supports the start of this innovative study in Crohn's disease with GLPG0634. Our experience within gastroenterology, combined with a novel alternative treatment for this disease may provide a greater benefit to patients in the future," said Scott Brun, M.D., vice president, pharmaceutical development, AbbVie.
"Galapagos and AbbVie are moving forward with GLPG0634, expanding the scope of the development program into inflammatory bowel disease. The innovative Phase II program in Crohn's disease is designed to move rapidly into Phase III when successful," said Onno van de Stolpe, chief executive officer of Galapagos. "Galapagos is in a strong financial position to fund the Crohn's program, in addition to a Phase IIb program with GLPG0634 in RA."